ACIP Votes Unanimously to Recommend Nirsevimab

Posted on by Kate Smith

Today, ACIP voted unanimously (10 YES – 0 NO for all votes) to recommend nirsevimab for use in infants <8 months born or entering their first RSV season, and for children aged 8-19 months who are at increased risk of RSV disease entering their second RSV season (agenda and slides). The Committee also voted for the inclusion of nirsevimab in VFC: Infants aged <8 months born during or entering their first RSV reason are recommended to receive one dose of nirsevimab (50 mg for infants <5 kg and 100 mg for infants ≥5kg) Children aged 8-19 months who are at Read More …

Improving the Vaccine Experience

Posted on by Kate Smith

Free, 1-hour webinar hosted by ImmunizeOrg, “Improving the Vaccination Experience: Reducing Pain and Anxiety for Children and Adults” at 1 p.m. ET on Feb 28. Anxiety about needles and injections affects as many as 2 out of 3 children and 1 out of 4 adults; this anxiety can contribute to dreading, delaying, or avoiding vaccinations, even when the importance of preventing illness is understood. The good news is that there are safe, effective, and practical steps that those who administer vaccines and vaccine recipients or their caregivers can take to reduce vaccination-related pain and anxiety and increase confidence in vaccination. Read More …